{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:17:22Z","timestamp":1787681842374,"version":"build-2784847793"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T00:00:00Z","timestamp":1352332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s00213-012-2912-9","type":"journal-article","created":{"date-parts":[[2012,11,7]],"date-time":"2012-11-07T08:17:05Z","timestamp":1352276225000},"page":"381-392","source":"Crossref","is-referenced-by-count":109,"title":["Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects"],"prefix":"10.1007","volume":"226","author":[{"given":"Katherine A.","family":"MacLean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad J.","family":"Reissig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Prisinzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,8]]},"reference":[{"key":"2912_CR1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00213-011-2470-6","volume":"220","author":"PH Addy","year":"2012","unstructured":"Addy PH (2012) Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology (Berl) 220:195\u2013204. doi: 10.1007\/s00213-011-2470-6","journal-title":"Psychopharmacology (Berl)"},{"key":"2912_CR2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/02791072.2009.10400531","volume":"41","author":"DN Albertson","year":"2009","unstructured":"Albertson DN, Grubbs LE (2009) Subjective effects of Salvia divinorum: LSD- or marijuana-like? J Psychoactive Drugs 41:213\u2013217","journal-title":"J Psychoactive Drugs"},{"key":"2912_CR3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.drugalcdep.2010.05.003","volume":"111","author":"MJ Baggott","year":"2010","unstructured":"Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J (2010) Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend 111:250\u2013256","journal-title":"Drug Alcohol Depend"},{"key":"2912_CR4","doi-asserted-by":"crossref","unstructured":"Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC (2011) Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug Alcohol Depend 114:61\u201367. doi: 10.1016\/j.drugalcdep.2010.09.006","DOI":"10.1016\/j.drugalcdep.2010.09.006"},{"key":"2912_CR5","volume-title":"Manual for the beck depression inventory-II","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown GK (1996) Manual for the beck depression inventory-II. Psychological Corporation, San Antonio"},{"key":"2912_CR6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-006-0639-1","volume":"190","author":"D Braida","year":"2007","unstructured":"Braida D, Limonta V, Pegorini S, Zani A, Guerini-Rocco C, Gori E, Sala M (2007) Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacol (Berl) 190:441\u2013448. doi: 10.1007\/s00213-006-0639-1","journal-title":"Psychopharmacol (Berl)"},{"key":"2912_CR7","doi-asserted-by":"crossref","unstructured":"Braida D, Limonta V, Capurro V, Fadda P, Rubino T, Mascia P, Zani A, Gori E, Fratta W, Parolaro D, Sala M (2008) Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry 63:286\u2013292. doi: 10.1016\/j.biopsych.2007.07.020","DOI":"10.1016\/j.biopsych.2007.07.020"},{"key":"2912_CR8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/pr.110.003244","volume":"63","author":"CW Cunningham","year":"2011","unstructured":"Cunningham CW, Rothman RB, Prisinzano TE (2011) Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev 63:316\u2013347. doi: 10.1124\/pr.110.003244","journal-title":"Pharmacol Rev"},{"key":"2912_CR9","volume-title":"BSI Brief Symptom Inventory: administration, scoring, and procedures manual","author":"LR Derogatis","year":"1993","unstructured":"Derogatis LR (1993) BSI Brief Symptom Inventory: administration, scoring, and procedures manual. National Computer Systems, Minneapolis"},{"key":"2912_CR10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1017\/S0033291700048017","volume":"13","author":"LR Derogatis","year":"1983","unstructured":"Derogatis LR, Melisaratos N (1983) The brief symptom inventory: an introductory report. Psychol Med 13:595\u2013605","journal-title":"Psychol Med"},{"issue":"Suppl 2","key":"2912_CR11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","volume":"31","author":"A Dittrich","year":"1998","unstructured":"Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Suppl 2):80\u201384","journal-title":"Pharmacopsychiatry"},{"key":"2912_CR12","first-page":"225","volume-title":"Parkinson\u2019s disease and movement disorders","author":"S Fahn","year":"1993","unstructured":"Fahn S, Tolosa E, Mar\u00edn C (1993) Clinical rating scale for tremor. In: Jankovic J, Tolosa E (eds) Parkinson\u2019s disease and movement disorders. Williams & Wilkins, Baltimore, pp 225\u2013234"},{"key":"2912_CR13","first-page":"738","volume":"1","author":"DH Ffytche","year":"1998","unstructured":"Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S (1998) The anatomy of conscious vision: an fMRI study of visual hallucinations. Nature 1:738\u2013742","journal-title":"Nature"},{"key":"2912_CR14","doi-asserted-by":"crossref","unstructured":"Gonzalez D, Riba J, Bouso JC, Gomez-Jarabo G, Barbanoj MJ (2006) Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85:157\u2013162. doi: 10.1016\/j.drugalcdep.2006.04.001","DOI":"10.1016\/j.drugalcdep.2006.04.001"},{"key":"2912_CR15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacol (Berl) 187:268\u2013283. doi: 10.1007\/s00213-006-0457-5","journal-title":"Psychopharmacol (Berl)"},{"key":"2912_CR16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BR, McCann UD, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacol (Berl) 218:649\u2013665. doi: 10.1007\/s00213-011-2358-5","journal-title":"Psychopharmacol (Berl)"},{"key":"2912_CR17","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/00004714-200112000-00025","volume":"21","author":"KR Hanes","year":"2001","unstructured":"Hanes KR (2001) Antidepressant effects of the herb Salvia divinorum: a case report. J Clin Psychopharmacol 21:634\u2013635","journal-title":"J Clin Psychopharmacol"},{"key":"2912_CR18","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/0021-8294.00085","volume":"40","author":"RW Hood","year":"2001","unstructured":"Hood RW, Ghorbani N, Watson PJ, Ghramaleki AH, Bing MN, Davison HK, Morris RJ, Williamson WP (2001) Dimensions of the mysticism scale: confirming the three-factor structure in the United States and Iran. J Sci Stud Relig 40:691\u2013705","journal-title":"J Sci Stud Relig"},{"key":"2912_CR19","first-page":"468","volume":"76","author":"H Isbell","year":"1956","unstructured":"Isbell H, Bellevile RE, Fraser HF, Wikler A, Logan CR (1956) Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. Arch Gen Psychiatry 76:468\u2013478","journal-title":"Arch Gen Psychiatry"},{"key":"2912_CR20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-642-66612-4_4","volume-title":"Drug addiction","author":"DR Jasinski","year":"1977","unstructured":"Jasinski DR (1977) Assessment of the abuse potential of morphine-like drugs (methods used in man). In: Martin WR (ed) Drug addiction. Springer, New York, pp 197\u2013258"},{"key":"2912_CR21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603\u2013620","journal-title":"J Psychopharmacol"},{"key":"2912_CR22","doi-asserted-by":"crossref","unstructured":"Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR (2011) Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115:150\u2013155. doi: 10.1016\/j.drugalcdep.2010.11.005","DOI":"10.1016\/j.drugalcdep.2010.11.005"},{"key":"2912_CR23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/02791072.2011.566500","volume":"43","author":"BC Kelly","year":"2011","unstructured":"Kelly BC (2011) Legally tripping: a qualitative profile of Salvia divinorum use among young adults. J Psychoactive Drugs 43:46\u201354","journal-title":"J Psychoactive Drugs"},{"key":"2912_CR24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00213-010-1819-6","volume":"210","author":"B Kivell","year":"2010","unstructured":"Kivell B, Prisinzano TE (2010) Kappa opioids and the modulation of pain. Psychopharmacol (Berl) 210:109\u2013119. doi: 10.1007\/s00213-010-1819-6","journal-title":"Psychopharmacol (Berl)"},{"key":"2912_CR25","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0022-3565(25)24372-5","volume":"238","author":"KM Kumor","year":"1986","unstructured":"Kumor KM, Haertzen CA, Johnson RE, Kocher T, Jasinski D (1986) Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther 238:960\u2013968","journal-title":"J Pharmacol Exp Ther"},{"key":"2912_CR26","doi-asserted-by":"crossref","unstructured":"Lange JE, Daniel J, Homer K, Reed MB, Clapp JD (2010) Salvia divinorum: effects and use among YouTube users. Drug Alcohol Depend 108:138\u2013140. doi: 10.1016\/j.drugalcdep.2009.11.010","DOI":"10.1016\/j.drugalcdep.2009.11.010"},{"key":"2912_CR27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0166-2236(88)90093-8","volume":"11","author":"A Mansour","year":"1988","unstructured":"Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988) Anatomy of CNS opioid receptors. Trends Neurosci 11:308\u2013314","journal-title":"Trends Neurosci"},{"key":"2912_CR28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt1971122part1245","volume":"12","author":"WR Martin","year":"1971","unstructured":"Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetmine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245\u2013258","journal-title":"Clin Pharmacol Ther"},{"key":"2912_CR29","volume-title":"Manual for the profile of mood states","author":"D McNair","year":"1971","unstructured":"McNair D, Lorr M, Droppleman L (1971) Manual for the profile of mood states. Education and industrial Testing Service, San Diego"},{"key":"2912_CR30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1749-6632.2000.tb06678.x","volume":"909","author":"NK Mello","year":"2000","unstructured":"Mello NK, Negus SS (2000) Interactions between kappa opioid agonists and cocaine. Preclinical studies. Ann N Y Acad Sci 909:104\u2013132","journal-title":"Ann N Y Acad Sci"},{"key":"2912_CR31","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00213-010-2103-5","volume":"214","author":"JE Mendelson","year":"2011","unstructured":"Mendelson JE, Coyle JR, Lopez JC, Baggott MJ, Flower K, Everhart ET, Munro TA, Galloway GP, Cohen BM (2011) Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacol (Berl) 214:933\u2013939. doi: 10.1007\/s00213-010-2103-5","journal-title":"Psychopharmacol (Berl)"},{"key":"2912_CR32","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.00005.2009","volume":"89","author":"JL Merrer","year":"2009","unstructured":"Merrer JL, Becker JAJ, Befort K, Kieffer BL (2009) Reward processing by the opioid system in the brain. Physiol Rev 89:1379\u20131412. doi: 10.1152\/physrev.00005.2009","journal-title":"Physiol Rev"},{"key":"2912_CR33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pbb.2009.09.002","volume":"94","author":"AS Morani","year":"2009","unstructured":"Morani AS, Kivell B, Prisinzano TE, Schenk S (2009) Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav 94:244\u2013249. doi: 10.1016\/j.pbb.2009.09.002","journal-title":"Pharmacol Biochem Behav"},{"key":"2912_CR34","first-page":"103","volume":"18","author":"J Ott","year":"1995","unstructured":"Ott J (1995) Ethnopharmacognosy and human pharmacology of Salvia divinorum and salvinorin A. Curare 18:103\u2013129","journal-title":"Curare"},{"key":"2912_CR35","volume-title":"Pharmacotheon: entheogenic drugs, their plant sources and history","author":"J Ott","year":"1996","unstructured":"Ott J (1996) Pharmacotheon: entheogenic drugs, their plant sources and history, 2nd edn. Natural Products Co., Kennewick","edition":"2"},{"key":"2912_CR36","first-page":"149","volume":"5","author":"WN Pahnke","year":"1969","unstructured":"Pahnke WN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin 5:149\u2013162","journal-title":"Int Psychiatry Clin"},{"key":"2912_CR37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/00952990.2011.600397","volume":"38","author":"BE Perron","year":"2012","unstructured":"Perron BE, Ahmedani BK, Vaughn MG, Glass JE, Abdon A, Wu LT (2012) Use of Salvia divinorum in a nationally representative sample. Am J Drug Alcohol Abus 38:108\u2013113. doi: 10.3109\/00952990.2011.600397","journal-title":"Am J Drug Alcohol Abus"},{"key":"2912_CR38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.lfs.2005.09.008","volume":"78","author":"TE Prisinzano","year":"2005","unstructured":"Prisinzano TE (2005) Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci 78:527\u2013531. doi: 10.1016\/j.lfs.2005.09.008","journal-title":"Life Sci"},{"key":"2912_CR39","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.biopsych.2012.06.012","volume":"72","author":"M Ranganathan","year":"2012","unstructured":"Ranganathan M, Schnakenburg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D\u2019Souza DC (2012) Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the \u03ba opioid agonist salvinorin A in humans. Biol Psychiatry 72:871\u2013879. doi: 10.1016\/j.biopsych.2012.06.012","journal-title":"Biol Psychiatry"},{"key":"2912_CR40","doi-asserted-by":"crossref","unstructured":"Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR (2012) High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacol (Berl). doi: 10.1007\/s00213-012-2680-6","DOI":"10.1007\/s00213-012-2680-6"},{"key":"2912_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.1977.10472020","volume":"9","author":"WA Richards","year":"1977","unstructured":"Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs 9:1\u201310","journal-title":"J Psychedelic Drugs"},{"key":"2912_CR42","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1073\/pnas.182234399","volume":"99","author":"BL Roth","year":"2002","unstructured":"Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99:11934\u201311939. doi: 10.1073\/pnas.182234399","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2912_CR43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-6147(03)00027-0","volume":"24","author":"DJ Sheffler","year":"2003","unstructured":"Sheffler DJ, Roth BL (2003) Salvinorin A: the \u201cmagic mint\u201d hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24:107\u2013109","journal-title":"Trends Pharmacol Sci"},{"key":"2912_CR44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0378-8741(94)90116-3","volume":"43","author":"DJ Siebert","year":"1994","unstructured":"Siebert DJ (1994) Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43:53\u201356","journal-title":"J Ethnopharmacol"},{"key":"2912_CR45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1037\/0096-3445.117.1.34","volume":"117","author":"JG Snodgrass","year":"1988","unstructured":"Snodgrass JG, Corwin J (1988) Pragmatics of measuring recognition memory: applications to dementia and amnesia. J Exp Psychol Gen 117:34\u201350","journal-title":"J Exp Psychol Gen"},{"key":"2912_CR46","volume-title":"Manual for the state-trait anxiety inventory","author":"CD Spielberger","year":"1983","unstructured":"Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA (1983) Manual for the state-trait anxiety inventory. Consulting Psychologist, Palo Alto"},{"key":"2912_CR47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98\u2013108","journal-title":"Arch Gen Psychiatry"},{"key":"2912_CR48","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25:1434\u20131452. doi: 10.1177\/0269881110382466","journal-title":"J Psychopharmacol"},{"key":"2912_CR49","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/0269881110385596","volume":"25","author":"HR Sumnall","year":"2011","unstructured":"Sumnall HR, Measham F, Brandt SD, Cole JC (2011) Salvia divinorum use and phenomenology: results from an online survey. J Psychopharmacol 25:1496\u20131507. doi: 10.1177\/0269881110385596","journal-title":"J Psychopharmacol"},{"key":"2912_CR50","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00018-011-0844-x","volume":"69","author":"HA Tejeda","year":"2012","unstructured":"Tejeda HA, Shippenburg TS, Henriksson R (2012) The dynorphin\/\u03ba-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci 69:857\u2013896. doi: 10.1007\/s00018-011-0844-x","journal-title":"Cell Mol Life Sci"},{"key":"2912_CR51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/02791072.1974.10471499","volume":"6","author":"IS Turek","year":"1974","unstructured":"Turek IS, Soskin RA, Kurland AA (1974) Methylenedioxyamphetamine (MDA) subjective effects. J Psychedelic Drugs 6:7\u201314","journal-title":"J Psychedelic Drugs"},{"key":"2912_CR52","doi-asserted-by":"crossref","unstructured":"Valdes 3rd LJ, Chang HM, Visger DC, Koreeda M (2001) Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum. Org Lett 3:3935\u20133937","DOI":"10.1021\/ol016820d"},{"key":"2912_CR53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1124\/mi.6.5.7","volume":"6","author":"TA Vortherms","year":"2006","unstructured":"Vortherms TA, Roth BL (2006) Salvinorin A: from natural product to human therapeutics. Mol Interv 6:257\u2013265. doi: 10.1124\/mi.6.5.7","journal-title":"Mol Interv"},{"key":"2912_CR54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00213-007-0948-z","volume":"196","author":"SL Walsh","year":"2008","unstructured":"Walsh SL, Chausmer AE, Strain EC, Bigelow GE (2008) Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacol (Berl) 196:143\u2013155. doi: 10.1007\/s00213-007-0948-z","journal-title":"Psychopharmacol (Berl)"},{"key":"2912_CR55","first-page":"53","volume":"2011","author":"LT Wu","year":"2011","unstructured":"Wu LT, Woody GE, Yang C, Li JH, Blazer DG (2011) Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil 2011:53\u201368. doi: 10.2147\/SAR.S17192","journal-title":"Subst Abuse Rehabil"},{"key":"2912_CR56","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00213-004-2087-0","volume":"179","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2005) Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacol (Berl) 179:551\u2013558. doi: 10.1007\/s00213-004-2087-0","journal-title":"Psychopharmacol (Berl)"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-012-2912-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-012-2912-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-012-2912-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T06:58:20Z","timestamp":1745132300000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-012-2912-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,8]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["2912"],"URL":"https:\/\/doi.org\/10.1007\/s00213-012-2912-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,8]]}}}